单位：[1]Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China[2]Peking Univ, Capital Med Univ, Beijing Shijitan Hosp, Sch Clin Med 9, Beijing, Peoples R China[3]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[4]Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
第一作者单位：[1]Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China[2]Peking Univ, Capital Med Univ, Beijing Shijitan Hosp, Sch Clin Med 9, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Lu Wenchao,Li Dandan,Wei Jingkai,et al.DPP-4 inhibitors and risk of venous thromboembolism: Analysis of the FDA adverse event reporting system database[J].PHARMACOEPIDEMIOLOGY and DRUG SAFETY.2019,28:561-562.
APA：
Lu, Wenchao,Li, Dandan,Wei, Jingkai,Sun, Lulu&Wang, Tiansheng.(2019).DPP-4 inhibitors and risk of venous thromboembolism: Analysis of the FDA adverse event reporting system database.PHARMACOEPIDEMIOLOGY and DRUG SAFETY,28,
MLA：
Lu, Wenchao,et al."DPP-4 inhibitors and risk of venous thromboembolism: Analysis of the FDA adverse event reporting system database".PHARMACOEPIDEMIOLOGY and DRUG SAFETY 28.(2019):561-562
